Telix Pharmaceuticals will showcase four presentations at ASCO GU 2025, including preliminary data from the CUPID study demonstrating proof-of-concept for their alpha therapy candidate in prostate cancer.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.